Last updated on November 2019

A Trial Investigating the Safety Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism

Brief description of study

During the first four weeks of the trial, participants will be randomly assigned to one of four groups: three groups will receive fixed doses of TransCon PTH and one group will receive placebo. TransCon PTH or placebo will be administered as a subcutaneous injection using a pre-filled injection pen. Neither trial participants nor their doctors will know who has been assigned to each group. After the four weeks, participants will continue in the trial as part of a long-term extension study. During the extension, all participants will receive TransCon PTH, with the dose adjusted to their individual needs. This is a global trial that will be conducted in, but not limited to, the United States, Canada, Germany, Denmark, and Norway.

Clinical Study Identifier: NCT04009291

Find a site near you

Start Over

Ascendis Pharma Investigational Site

Northport, NY United States
  Connect »